Author | Jared Kaltwasser


Updated ALTERNATIVE Results Favor Dual HER2 Blockade in HER2+/HR+ Metastatic Breast Cancer

September 22, 2020

“Dual targeting of HER2-positive tumors with [trastuzumab] and [lapatinib] is beneficial because of differing mechanisms of action and because of the well-characterized synergistic interaction between them in HER2 [breast cancer] models."

PET-Guided Therapy Improves Outcomes in Patients With Limited-Stage DLBCL

August 27, 2020

Use of interim positron emission tomography scans to direct patient care has established a new standard treatment approach for patients with limited-stage diffuse large B-cell lymphoma. These findings are from the Intergroup National Clinical Trials Network S1001 study.